Saltar al contenido

Qiagen N.v. (QGEN) stock: revenue, earnings & dividend

Qiagen N.v. (QGEN, NYSE): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener QGEN · NYSE Pharma & Biotech NL-

Key figures

Fiscal year
2025
Revenue
2.09 bn $
Revenue growth
5.7 %
Revenue growth 5y (p.a.)
2.3 %
Net income
425 m $
Net margin
20.3 %
Operating margin
22.3 %
Earnings per share (diluted)
1.94 $
Dividend per share
0.25 $
Payout ratio
12.9 %
Consecutive dividend years
1 years
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
6.28 bn $
Equity
3.78 bn $
Equity ratio
60.2 %
Return on equity
11.3 %
Cash
839 m $
Operating cash flow
654 m $
Free cash flow
453 m $
Shares outstanding
216,920,735

History

Revenue by fiscal year

2016 1.34 bn $
2017 1.42 bn $
2018 1.5 bn $
2019 1.53 bn $
2020 1.87 bn $
2021 2.25 bn $
2022 2.14 bn $
2023 1.97 bn $
2024 1.98 bn $
2025 2.09 bn $

Net income by fiscal year

2016 80.4 m $
2017 40.4 m $
2018 190 m $
2019 -41.46 m $
2020 359 m $
2021 513 m $
2022 423 m $
2023 341 m $
2024 83.6 m $
2025 425 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20252.09 bn $425 m $1.94 $0.25 $654 m $
20241.98 bn $83.6 m $0.37 $–674 m $
20231.97 bn $341 m $1.48 $–459 m $
20222.14 bn $423 m $1.84 $–715 m $
20212.25 bn $513 m $2.21 $–639 m $
20201.87 bn $359 m $1.53 $–458 m $
20191.53 bn $-41.46 m $-0.18 $–331 m $
20181.5 bn $190 m $0.82 $–359 m $
20171.42 bn $40.4 m $0.17 $–287 m $
20161.34 bn $80.4 m $0.34 $–342 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)